Histopathology Images Based Survival Prediction of Glioma Patients Using Artificial Intelligence

NCT04215224 · tracked via the Priya Life Science China tracker

Sponsor

The First Affiliated Hospital of Zhengzhou University

Phase

Observational

Started

2017-01-01

Last updated

2021-02-08

Condition(s) studied

Glioma

Investigational drug(s) / intervention(s)

Histopathology images based survival prediction for glioma patients

Histopathology images based survival prediction for glioma patients: Histopathology images based survival prediction of glioma patients in the frame of molecular pathology by leveraging AI

Study summary

This registry aims to collect clinical, molecular and histopathology imaging including detailed survival data, clinical parameters, molecular pathology (1p/19q codeletion, MGMT methylation, IDH and TERTp mutations, etc) and images of HE slices in primary gliomas. By leveraging artificial intelligence, this registry will seek to construct and refine hstopathology imaging based algorithms that able to predict patients' survivals in the frame of molecular pathology or subgroups of gliomas.

Eligibility

Sex

ALL

Min age

1 Year

Max age

90 Years

Healthy volunteers

Inclusion Criteria: * Patients must have radiologically and histologically confirmed diagnosis of primary glioma * Life expectancy of greater than 3 months * Must receive tumor resection * Signed informed consent Exclusion Criteria: * No gliomas * No sufficient amount of tumor tissues for detection of molecular pathology * Patients who are pregnant or breast feeding * Patients who are suffered from severe systematic malfuctions

Primary outcome measure(s)

AUC of survival prediction performance — up to 10 years
AUC of survival prediction performance=sensitivity+specificity-1

Trial sites (1)

Facility	City	Region	Status
Department of Neurosurgery, First Affiliated Hospital of Zhengzhou University	Zhengzhou	Henan	Recruiting

More The First Affiliated Hospital of Zhengzhou University trials in China

Comparison of the Efficacy and Safety of Immunoadsorption and Intravenous Immunoglobulin for Guillain-Barre Syndrome Starting soon

Azoospermia Patients Recruiting

IBI363 Plus Bevacizumab With or Without Nab-Paclitaxel for Second-Line Treatment of Advanced Gastric Cancer Starting soon

A Phase II Exploratory Clinical Trial of Multiple Drug Combinations in the Treatment of Advanced Esophageal Squamous Cell Carcinoma Recruiting

RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer Starting soon

Other trials for the same condition

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations Active, not recruiting

Vorasidenib Guided by AGX PET in Recurrent/Low-grade Glioma Starting soon

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) Recruiting

Histopathology Images Based Prediction of Molecular Pathology in Glioma Using Artificial Intelligence Recruiting

MR Based Prediction of Molecular Pathology in Glioma Using Artificial Intelligence Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04215224 on ClinicalTrials.gov ↗ ← All trials in China